Lipocine (LPCN) Q1 2026 earnings summary

Executive summary

• Focused on oral drug delivery for CNS disorders, liver disease, and hormone supplementation, with a pipeline including LPCN 1154 (postpartum depression), LPCN 2201 (major depressive disorder), LPCN 2101 (epilepsy), and TLANDO (testosterone replacement therapy).

• TLANDO is licensed to partners in the U.S., Canada, South Korea, GCC, and Brazil, generating royalty and milestone revenues, with ongoing partnership discussions for additional regions.

• LPCN 1154 Phase 3 trial for postpartum depression did not meet its primary endpoint, but post hoc analysis suggests benefit in patients with psychiatric history; further regulatory engagement and strategic options are being explored.

• Applied for breakthrough therapy and fast track designations for LPCN 1154; awaiting FDA feedback.

Financial highlights

• Q1 2026 revenue was $119,000, up from $94,000 in Q1 2025, all from TLANDO royalties.

• Net loss for Q1 2026 was $3.7 million, or $(0.54) per diluted share, compared to $1.9 million, or $(0.35) per diluted share, in Q1 2025, driven by increased R&D expenses for LPCN 1154.

• Cash, cash equivalents, and marketable securities totaled $24.7 million as of March 31, 2026, up from $14.9 million at year-end 2025, bolstered by a $12 million equity raise.

• Operating expenses rose to $3.97 million in Q1 2026 from $2.18 million in Q1 2025, mainly due to clinical trial costs.

• Research and development expenses increased to $2.8 million from $1.1 million year-over-year, mainly due to LPCN 1154 clinical study costs.

Outlook and guidance

• Existing capital resources are expected to fund operations through at least May 2027, but additional capital will be needed for expanded clinical activities.

• Awaiting FDA feedback on breakthrough therapy and fast track designations for LPCN 1154 and planning to submit a validation study protocol.

• Plans to complete full analysis of Phase 3 LPCN 1154 data and present at upcoming medical conferences.

• Continued pursuit of partnerships for pipeline assets and out-licensing opportunities for TLANDO in new territories.